26 03, 2024 Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals Neal Evan Caminsky2024-03-26T15:02:33-04:00March 26, 2024|Funded Research Results, Pillar 10|
19 03, 2024 Pillar 10 Antiviral Team Reflects on Three Years of Breakthrough Research Neal Evan Caminsky2024-04-04T11:50:46-04:00March 19, 2024|Pillar 10, Hot Topic|
11 10, 2023 Use of whole genome sequencing to identify low-frequency mutations in SARS-COV-2 patients treated with remdesivir Neal Evan Caminsky2023-10-10T16:42:55-04:00October 11, 2023|Funded Research Results, Pillar 10|
29 08, 2023 A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariants Neal Evan Caminsky2023-08-29T11:51:33-04:00August 29, 2023|Funded Research Results, Pillar 10|
31 07, 2023 Prevalence of Low-Frequency, Antiviral Resistance Variants in SARS-CoV-2 Isolates in Ontario, Canada, 2020-23 Neal Evan Caminsky2023-07-31T16:28:22-04:00July 31, 2023|Funded Research Results, Pillar 10|
17 07, 2023 Synthetic Analogs of the Sponge Sesterterpenoid Alotaketal C are Potent Inhibitors of SARS-CoV-2 Omicron BA.1 and BA.5 Infections of Human Lung Cells Neal Evan Caminsky2023-07-19T13:13:08-04:00July 17, 2023|Funded Research Results, Pillar 10|
20 04, 2023 Berbamine suppresses intestinal SARS-CoV-2 infection via a BNIP3-dependent autophagy blockade Neal Evan Caminsky2023-10-13T10:18:47-04:00April 20, 2023|Funded Research Results, Pillar 10|
9 01, 2023 Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics Neal Evan Caminsky2023-07-17T15:42:02-04:00January 9, 2023|Funded Research Results, Pillar 10|
28 03, 2022 Promising new molecule discovered in Canada shown to block SARS-CoV-2 could be developed as a nasal spray drug for COVID-19 Neal Evan Caminsky2022-11-15T09:12:00-05:00March 28, 2022|Funded Research Results, Pillar 10|
